Title : In vivo targeting of B-cell lymphoma with glycan ligands of CD22.

Pub. Date : 2010 Jun 10

PMID : 20181615






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A current clinical target for B-cell lymphoma is CD22, a B-cell-specific member of the sialic acid binding Ig-like lectin (siglec) family that recognizes alpha2-6-linked sialylated glycans as ligands. Polysaccharides CD22 molecule Homo sapiens
2 Here, we describe a novel approach for targeting B lymphoma cells with doxorubicin-loaded liposomal nanoparticles displaying high-affinity glycan ligands of CD22. Polysaccharides CD22 molecule Homo sapiens